



**AWMSG ADVICE SUPERSEDED BY  
NICE GUIDANCE (TA439)  
NICE GUIDANCE ISSUED MARCH 2017**

(Refer to NICE website for full guidance on NICE recommendations, including any specific restrictions on the use of the technology)

**Final Appraisal Recommendation  
Advice No: 4315 – December 2015**

**Cetuximab (Erbix<sup>®</sup>) 5 mg/ml solution for infusion**

**Submission by Merck Serono Ltd**

**Recommendation of AWMSG**

**Cetuximab (Erbix<sup>®</sup>) is recommended as an option for restricted use within NHS Wales for the first-line treatment of patients with epidermal growth factor receptor (EGFR)-expressing, RAS wild-type metastatic colorectal cancer in combination with irinotecan-based chemotherapy or in combination with FOLFOX. This recommendation applies only in circumstances where the approved Wales Patient Access Scheme is utilised.**

**Cetuximab (Erbix<sup>®</sup>) is not recommended for use within NHS Wales for the treatment of patients with EGFR-expressing, RAS wild-type metastatic colorectal cancer as a single agent in patients who have failed oxaliplatin- and irinotecan-based therapy and who are intolerant to irinotecan.**

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 2407) which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by the Minister for Health and Social Services and will be considered for review every three years.



NICE has accredited the process used by the All Wales Medicines Strategy Group (AWMSG) to produce its final appraisal recommendation. Accreditation is valid for 5 years from October 2011. More information on accreditation can be viewed at [www.evidence.nhs.uk](http://www.evidence.nhs.uk).

For full details on our accreditation visit: [www.nice.org.uk/accreditation](http://www.nice.org.uk/accreditation).

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group. Final Appraisal Recommendation – 4315:  
cetuximab (Erbitux<sup>®</sup>) 5 mg/ml solution for infusion. December 2015.

